Drug interactions
Encorafenib + Rimegepant
Severity: Major
Encorafenib and Rimegepant: major interaction.
Last updated Sources: US FDA label
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Encorafenib both inhibits and induces CYP3A4, so its net effect on rimegepant exposure is unpredictable. Rimegepant could be either too high or too low.
What this interaction means in plain words
Encorafenib and Rimegepant can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Encorafenib belongs to Oncology; Rimegepant belongs to Central Nervous System.
Why it happens
Mixed CYP3A4 inhibition and induction by encorafenib alters rimegepant metabolism unpredictably.
What to do
Avoid coadministration and use an alternative acute migraine treatment.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Encorafenib and Rimegepant, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
References
Other interactions of Rimegepant
Other interactions of Encorafenib
Frequently asked questions
Can I take Encorafenib with Rimegepant?
MediHelp rates the interaction as major. Encorafenib and Rimegepant can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Encorafenib both inhibits and induces CYP3A4, so its net effect on rimegepant exposure is unpredictable. Rimegepant could be either too high or too low.
How serious is the interaction between Encorafenib and Rimegepant?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid coadministration and use an alternative acute migraine treatment.
What other medicines interact with Rimegepant?
MediHelp also lists interactions of Rimegepant with, for example, Amobarbital, Atazanavir, Butabarbital. The full list is on the Rimegepant page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
